Research programme: GPR84 antagonists - Liminal BioSciences
Alternative Names: GPR84 antagonist program - Liminal BioSciencesLatest Information Update: 11 Aug 2023
At a glance
- Originator Liminal BioSciences
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action GPR84 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Metabolic disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Discontinued Renal fibrosis
Most Recent Events
- 08 Aug 2023 Liminal Biosciences announces intention to submit a Clinical Trial Application (CTA) in H2 2023
- 08 Aug 2023 Liminal Biosciences plans a phase I first-in-human clinical trial in H2 2023
- 13 Jul 2023 Discontinued - Preclinical for Renal fibrosis in Canada (unspecified route) (Liminal BioSciences pipeline, July 2023)